Apixaban in a Morbid Obese Patient with Atrial Fibrillation: A Clinical Experience Using the Plasmatic Drug Evaluation

We present the case of a 45-year-old man with atrial fibrillation and morbid obesity (weight 128 kg, height 168 cm, BMI 45.4) who was switched from Warfarin 5 mg once daily to Apixaban 5 mg twice daily because he did not achieve at least 60% of the time in therapeutic range. We performed serial dete...

Descripción completa

Detalles Bibliográficos
Autores principales: Russo, Vincenzo, Paccone, Andrea, Rago, Anna, Maddaloni, Valeria, Iafusco, Dario, Proietti, Riccardo, Atripaldi, Umberto, D’Onofrio, Antonio, Golino, Paolo, Nigro, Gerardo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7061727/
https://www.ncbi.nlm.nih.gov/pubmed/32184692
http://dx.doi.org/10.2147/JBM.S229526
_version_ 1783504444120367104
author Russo, Vincenzo
Paccone, Andrea
Rago, Anna
Maddaloni, Valeria
Iafusco, Dario
Proietti, Riccardo
Atripaldi, Umberto
D’Onofrio, Antonio
Golino, Paolo
Nigro, Gerardo
author_facet Russo, Vincenzo
Paccone, Andrea
Rago, Anna
Maddaloni, Valeria
Iafusco, Dario
Proietti, Riccardo
Atripaldi, Umberto
D’Onofrio, Antonio
Golino, Paolo
Nigro, Gerardo
author_sort Russo, Vincenzo
collection PubMed
description We present the case of a 45-year-old man with atrial fibrillation and morbid obesity (weight 128 kg, height 168 cm, BMI 45.4) who was switched from Warfarin 5 mg once daily to Apixaban 5 mg twice daily because he did not achieve at least 60% of the time in therapeutic range. We performed serial determinations of apixaban plasma concentration (at 2, 6, 12, 24 hrs after intake) showing drug levels within reference range, even when the patient lose weight.
format Online
Article
Text
id pubmed-7061727
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-70617272020-03-17 Apixaban in a Morbid Obese Patient with Atrial Fibrillation: A Clinical Experience Using the Plasmatic Drug Evaluation Russo, Vincenzo Paccone, Andrea Rago, Anna Maddaloni, Valeria Iafusco, Dario Proietti, Riccardo Atripaldi, Umberto D’Onofrio, Antonio Golino, Paolo Nigro, Gerardo J Blood Med Case Report We present the case of a 45-year-old man with atrial fibrillation and morbid obesity (weight 128 kg, height 168 cm, BMI 45.4) who was switched from Warfarin 5 mg once daily to Apixaban 5 mg twice daily because he did not achieve at least 60% of the time in therapeutic range. We performed serial determinations of apixaban plasma concentration (at 2, 6, 12, 24 hrs after intake) showing drug levels within reference range, even when the patient lose weight. Dove 2020-03-03 /pmc/articles/PMC7061727/ /pubmed/32184692 http://dx.doi.org/10.2147/JBM.S229526 Text en © 2020 Russo et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Case Report
Russo, Vincenzo
Paccone, Andrea
Rago, Anna
Maddaloni, Valeria
Iafusco, Dario
Proietti, Riccardo
Atripaldi, Umberto
D’Onofrio, Antonio
Golino, Paolo
Nigro, Gerardo
Apixaban in a Morbid Obese Patient with Atrial Fibrillation: A Clinical Experience Using the Plasmatic Drug Evaluation
title Apixaban in a Morbid Obese Patient with Atrial Fibrillation: A Clinical Experience Using the Plasmatic Drug Evaluation
title_full Apixaban in a Morbid Obese Patient with Atrial Fibrillation: A Clinical Experience Using the Plasmatic Drug Evaluation
title_fullStr Apixaban in a Morbid Obese Patient with Atrial Fibrillation: A Clinical Experience Using the Plasmatic Drug Evaluation
title_full_unstemmed Apixaban in a Morbid Obese Patient with Atrial Fibrillation: A Clinical Experience Using the Plasmatic Drug Evaluation
title_short Apixaban in a Morbid Obese Patient with Atrial Fibrillation: A Clinical Experience Using the Plasmatic Drug Evaluation
title_sort apixaban in a morbid obese patient with atrial fibrillation: a clinical experience using the plasmatic drug evaluation
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7061727/
https://www.ncbi.nlm.nih.gov/pubmed/32184692
http://dx.doi.org/10.2147/JBM.S229526
work_keys_str_mv AT russovincenzo apixabaninamorbidobesepatientwithatrialfibrillationaclinicalexperienceusingtheplasmaticdrugevaluation
AT pacconeandrea apixabaninamorbidobesepatientwithatrialfibrillationaclinicalexperienceusingtheplasmaticdrugevaluation
AT ragoanna apixabaninamorbidobesepatientwithatrialfibrillationaclinicalexperienceusingtheplasmaticdrugevaluation
AT maddalonivaleria apixabaninamorbidobesepatientwithatrialfibrillationaclinicalexperienceusingtheplasmaticdrugevaluation
AT iafuscodario apixabaninamorbidobesepatientwithatrialfibrillationaclinicalexperienceusingtheplasmaticdrugevaluation
AT proiettiriccardo apixabaninamorbidobesepatientwithatrialfibrillationaclinicalexperienceusingtheplasmaticdrugevaluation
AT atripaldiumberto apixabaninamorbidobesepatientwithatrialfibrillationaclinicalexperienceusingtheplasmaticdrugevaluation
AT donofrioantonio apixabaninamorbidobesepatientwithatrialfibrillationaclinicalexperienceusingtheplasmaticdrugevaluation
AT golinopaolo apixabaninamorbidobesepatientwithatrialfibrillationaclinicalexperienceusingtheplasmaticdrugevaluation
AT nigrogerardo apixabaninamorbidobesepatientwithatrialfibrillationaclinicalexperienceusingtheplasmaticdrugevaluation

Ejemplares similares